Petrillo M, et al. - Researchers conducted a systematic review of cytoreductive surgery and bevacizumab-containing chemotherapy in advanced ovarian cancer (AOC). In this work, the incorporation of bevacizumab into first-line chemotherapy in women with AOC was not associated with increased morbidities before and after cytoreductive surgery.